Docket #: S18-278
Hypoxia-mediated resistance of Homologous recombination-deficient cancer cells to PARP inhibitors
Stanford researcher's invivo studies find that combining PARP inhibitors with a hypoxia activated prodrug delays tumor growth.
We are asking parties interested in commercializing this technology to please contact Stanford OTL by Friday, March 29, 2019.
Applications
- Combining PARP inhibitors with Hypoxia-targeting drugs in HR deficient cancer cells
Advantages
- Combining PARP inhibitors with Tirapazamine (hypoxia-activated drug) shows significantly higher tumor killing effects when compared to each monotherapy.
Patents
- Published Application: WO2020118251
Similar Technologies
-
Blocking metastasis in liver cancer with cytokine inhibition S19-137Blocking metastasis in liver cancer with cytokine inhibition
-
Novel Azapodophyllotoxin Derivatives for Treatment of Lymphoma and Kidney Cancer S19-387Novel Azapodophyllotoxin Derivatives for Treatment of Lymphoma and Kidney Cancer
-
DNA Repair Compounds to Prevent Cancer S10-253DNA Repair Compounds to Prevent Cancer